Results 31 to 40 of about 2,541 (178)

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Innovative Design and Practical Reflections on Teaching Ideological and Political Aspects of ‘Pharmacoeconomics’ in the Digital Era

PSU Medical Journal
Objective: This study examines the innovative design and practical application of ideological and political (IP) teaching in the Pharmaceutical Economics course in a digitally evolving educational landscape. It seeks to effectively integrate IP education
Zaixian Yang, Ruo Lin, Jia Li, Siqi Yin, Ji Li, Jian Yang   +5 more
semanticscholar   +1 more source

Healthcare Costs Following Medical Gender‐Affirmation: Evidence From Whole‐of‐Population Australian Administrative Data

Health Economics, EarlyView.
ABSTRACT Gender incongruence in trans and nonbinary (“trans”) populations is often associated with psychological distress and increased demand for mental healthcare. Gender‐affirming hormone therapy (GAHT) is a key component of care for many trans people, yet long‐term evidence around its cost implications remains limited despite increasing uptake and ...
Karinna Saxby, Dennis Petrie, Brendan J. Nolan   +2 more
wiley   +1 more source

Pharmaco-Economics: The Cost of Health

Pharmatutor, 2019
Pharmacoeconomics has been characterized as the depiction and examination of the cost of medication treatment to healthcare frameworks and society.
A. K. Mohiuddin
semanticscholar   +1 more source

Identification of drugs-related problems and pharmacists’ interventions in a hospital in Southern Brazil

Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde, 2022
Objectives: to identify, describe and analyze drug-related problems (DRPs) and pharmaceutical interventions (PIs) in medical prescriptions of a hospital and estimate their economic impact on the health institution.
Inaê A SPEZIA, Helena I. CIMAROSTI
doaj   +1 more source

A patient‐centered conceptual model and measurement framework for migraine experience developed by the Migraine Clinical Outcome Assessment System

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To develop a comprehensive, evidence‐based, patient‐centered conceptual model of migraine and to derive a measurement framework for the development or selection of clinical outcome assessments used in clinical trials of treatments for migraine.
Rikki Mangrum, Alexandra L. Bryant, Carrie R. Houts, James S. McGinley, Dawn C. Buse, Richard B. Lipton, R. J. Wirth   +6 more
wiley   +1 more source

Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure

Frontiers in Pharmacology, 2021
Introduction: Biosimilar medicines are considered promising alternatives to new biologicals with high price tags. The extent of savings resulting from biosimilar use depends on their price and uptake, which are largely shaped by pricing, reimbursement ...
Sabine Vogler, Peter Schneider, Martin Zuba, Reinhard Busse, Dimitra Panteli   +4 more
doaj   +1 more source

Pharmacoeconomic Evaluation of Homeopathy: Assessing Efficacy, Economics, and Policy Perspectives

Journal of Pharmacoeconomics and Pharmaceutical Management
Background: In contemporary healthcare, evidence-based practices are fundamental for ensuring optimal patient outcomes and resource allocation. Essential steps for conducting pharmacoeconomic studies in homeopathy involve study design, intervention ...
Aditya Dilipkumar Patil, S. Singh
semanticscholar   +1 more source

Cardiovascular‐Kidney‐Metabolic Syndrome: Conceptualising an Approach to Health Economic Modelling

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 7802-7813, September 2026.
ABSTRACT Aims Cardiovascular‐kidney‐metabolic (CKM) syndrome has developed into a global public health crisis. Although integrated care is increasingly used to treat patients with CKM, current health economic models fail to capture the value of considering the CKM syndrome as a unified condition.
Volker Foos, Jieling Chen, Phil McEwan, Marc Evans, Pardeep S. Jhund, Paul R. Kalra, Hongtu Zhu, David C. Wheeler, Geraint Roberts, Martin R. Cowie, Andrew H. Briggs   +10 more
wiley   +1 more source

Evaluation of awareness about pharmacoeconomics in postgraduate students of a tertiary care teaching hospital: a questionnaire based observational study

, 2017
Pharmacoeconomics which is a sub-discipline of healtheconomics has been defined as “the description and analysis of the costs of drug therapy to healthcare systems and society”.
Rohini Gupta, Pavan Malhotra
semanticscholar   +1 more source